Evidence map›Paper›PMID 34278517›Full record

ArticleCancer immunology, immunotherapy : CII2022

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.

Da Hyun Kang, Chaeuk Chung, Pureum Sun, Da Hye Lee, Song-I Lee, Dongil Park, Jeong Suk Koh, Yoonjoo Kim, Hyon-Seung Yi, Jeong Eun Lee

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Da Hyun KangDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0002-3495-0931
Chaeuk ChungDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0002-3978-0484
Pureum SunCollege of Medicine, Research Institute for Medical Sciences, Chungnam National University, Daejeon, Korea.
Da Hye LeeCollege of Medicine, Research Institute for Medical Sciences, Chungnam National University, Daejeon, Korea.
Song-I LeeDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0001-8372-4511
Dongil ParkDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0001-7329-1724
Jeong Suk KohDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0002-4251-7310
Yoonjoo KimDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0002-9028-0872
Hyon-Seung YiDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea.ORCID https://orcid.org/0000-0002-3767-1954
Jeong Eun LeeDepartment of Internal Medicine, College of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, Korea. jelee0210@cnu.ac.kr.ORCID http://orcid.org/0000-0001-6173-2748
Chungnam National University · KR

Funding

Korean Association for the Study of Targeted Therapy (KASTT) KASTT-20190211National Research Foundation of Korea NRF-2019R1C1C1008864
6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have become the standard of care for a variety of cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the frequency of pseudoprogression and hyperprogression in lung cancer patients treated with ICIs in the real world and aimed to discover a novel candidate marker to distinguish pseudoprogression from hyperprogression soon after ICI treatment.

methodsThis study included 74 patients with advanced NSCLC who were treated with PD-1/PD-L1 inhibitors at Chungnam National University Hospital (CNUH) between January 2018 and August 2020. Chest X-rays were examined on day 7 after the first ICI dose to identify changes in the primary mass, and the response was assessed by computed tomography (CT). We evaluated circulating regulatory T (Treg) cells using flow cytometry and correlated the findings with clinical outcomes.

resultsThe incidence of pseudoprogression was 13.5%, and that of hyperprogression was 8.1%. On day 7 after initiation of treatment, the frequency of CD4

conclusionCirculating Treg cells represent a promising potential dynamic biomarker to predict efficacy and differentiate atypical responses, including pseudoprogression and hyperprogression, after immunotherapy in patients with NSCLC.

Indexed as

Lymphocyte CountMolecular Targeted TherapyAgedAged, 80 and overB7-H1 AntigenBiomarkersFemaleHumansImmune Checkpoint InhibitorsImmunophenotypingLung NeoplasmsMaleMiddle AgedPrognosisProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryB7-H1 AntigenBiomarkersCD274 protein, humanImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHyperprogressionImmunotherapyLung cancerPD-1/PD-L1 inhibitorPseudoprogressionRegulatory T cell

Identifiers

PMID34278517
PMCPMC8854239
OpenAlexW3185957320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.